PLETAL
LOE ApproachingNDAORALTABLET
Approved
Jan 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PLETAL is an oral tablet approved in 1999 for an undisclosed indication; the generic name and mechanism of action are not provided in available data. It is currently in late-stage lifecycle with loss of exclusivity approaching. The drug's therapeutic area and patient population cannot be determined from available information.
LOE Approaching
As LOE approaches, the brand team is likely in defensive mode with reduced commercial headcount; career growth opportunities may be limited unless repositioning or new indication launches are planned.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions
Started Dec 2008
44 enrolled
Intermittent Claudication
Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg
Started Mar 2004
44 enrolled
Healthy
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Started Oct 2001
75 enrolled
Raynaud's Disease
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Started Oct 2001
75 enrolled
Raynaud's Disease
Worked on PLETAL at Otsuka? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.